#United States #Research Triangle Park #Morrisville #Biologics #Solvias

Solvias Expands Its Global Reach with a New Center for Excellence

In a major step towards enhancing its capabilities in biopharmaceutical innovation, Solvias has opened a cutting-edge Center of Excellence focused on biologics and cell and gene therapy in the Research Triangle Park (RTP), North Carolina. This advanced facility, spanning an impressive 50,000 square feet, represents Solvias's commitment to accelerating the development and commercialization of transformative therapies aimed at treating cancer and rare diseases.

Location and Facilities

Situated in the heart of the RTP, the new center is the flagship location for Solvias in North America, offering analytical services specifically designed for large molecules. This state-of-the-art facility is set to create approximately 200 new jobs in the Raleigh-Durham area over the next three years. The opening of the center will occur in two phases:

• - Phase 1: Encompasses a 20,000 square foot space for cGMP release testing, featuring cell-based potency assays and molecular tests, which is ready for immediate operations.
• - Phase 2: Set to launch in July 2025, this addition will provide an extra 30,000 square feet dedicated to stability testing and advanced biophysical characterization.

Advanced Infrastructure

Equipped with cutting-edge analytical instruments, automated laboratory processes, and sophisticated digital management systems, the new facility will conduct comprehensive GMP testing for cell and gene therapies, monoclonal antibodies (mAbs), and additional biological drugs from preclinical phases all the way through to commercial release. As Archie Cullen, CEO of Solvias, noted, “The RTP Center is a milestone in Solvias's global growth strategy. By combining our team's expertise with advanced technology, we aim to set a new standard in delivering high-quality, reliable analytical support.”

Commitment to Clients

The company is focused on empowering clients with its analytical expertise. Ilya Koltover, the Chief Commercial Officer, emphasized that they are dedicated to recruiting top talent as technical partners for clients, enabling faster and more efficient therapy introductions to the market. “With this investment, we aspire to become an integral part of the U.S. biopharmaceutical innovation ecosystem,” Koltover stated.

Expanding Global Presence

The establishment of this new Center of Excellence expands Solvias's global network to six centers, marking the second facility in North America. Founded in Switzerland and renowned for its CMC (Chemistry, Manufacturing, and Controls) services in the life sciences industry, Solvias adheres to the highest standards set by ISO, GMP, GLP, and FDA. Their expertise extends across small molecules, biologics, and both cell and gene therapies, providing comprehensive end-to-end solutions from raw material testing to drug release and active pharmaceutical ingredient (API) development.

For further information about Solvias’s new Center of Excellence in RTP, interested parties can visit solvias.com.

Conclusion

As Solvias continues to establish itself as a leader in CMC services, the new facility in Research Triangle Park not only strengthens its operational capabilities but also provides critical support for the development of pioneering therapies. This initiative is a clear testament to the growing intersection of science and technology in enhancing patient care across the globe.